Monday, September 13, 2021 12:57:37 PM
Cardiff Oncology said the program is evaluating onvansertib in combination with standard-of-care Folfiri/bevacizumab to treat certain colorectal cancer patients.
"Our Phase 1b/2 trial continues to generate data suggesting that the addition of onvansertib to SOC results in an objective response rate and median progression-free survival that substantially exceed those previously achieved with SOC alone," said Katherine L. Ruffner, chief medical officer.
New York Yankees and Duke Basketball
Recent CRDF News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:06:55 PM
- Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:00:13 PM
- Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/17/2024 10:10:38 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/03/2024 08:06:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:03:35 PM
- Cardiff Oncology to Present at the Jefferies Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 08:05:00 PM
- Cardiff Oncology to Present at Upcoming Investor Conferences in May • GlobeNewswire Inc. • 05/13/2024 08:05:00 PM
- Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update • GlobeNewswire Inc. • 04/25/2024 08:05:00 PM
- Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study • GlobeNewswire Inc. • 04/08/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:40:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:40:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:39:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:39:40 PM
- Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 • GlobeNewswire Inc. • 03/06/2024 09:05:00 PM
- Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:07:00 PM
- Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC • GlobeNewswire Inc. • 02/29/2024 09:06:00 PM
- Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:00:21 PM
- Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:01:34 PM
- Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research • PR Newswire (US) • 01/17/2024 03:30:00 PM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM